Abstract
Snake venom disintegrins are the natural products that have been investigated as potent inhibitors of various integrins. Functionally, disintegrins can be divided into three groups according to their integrin selectivity and presence of specific, active motifs. This classification includes RGD-disintegrins, MLD-disintegrins, and KTS-disintegrins. RGD-disintegrins have been the most intensively investigated, and their research resulted in design and synthesis of new pharmaceutical compounds, eptifibatide and tirofiban that are currently being evaluated for the therapy of acute coronary ischaemic syndrome. MLD- and KTS-disintegrins are specific for leukocyte integrins and collagen receptors, respectively, and are being investigated in the new fields of pharmaceutical research. This review summarizes the biological activities of snake venom disintegrins, as well as discusses their potential in the study of the pharmacology of various human diseases.
Keywords: glycoproteins, monoclonal antibodies, c-lectin type proteins, fibronectin, cysteines, eptifibatide
Current Pharmaceutical Design
Title: Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Volume: 11 Issue: 7
Author(s): Cezary Marcinkiewicz
Affiliation:
Keywords: glycoproteins, monoclonal antibodies, c-lectin type proteins, fibronectin, cysteines, eptifibatide
Abstract: Snake venom disintegrins are the natural products that have been investigated as potent inhibitors of various integrins. Functionally, disintegrins can be divided into three groups according to their integrin selectivity and presence of specific, active motifs. This classification includes RGD-disintegrins, MLD-disintegrins, and KTS-disintegrins. RGD-disintegrins have been the most intensively investigated, and their research resulted in design and synthesis of new pharmaceutical compounds, eptifibatide and tirofiban that are currently being evaluated for the therapy of acute coronary ischaemic syndrome. MLD- and KTS-disintegrins are specific for leukocyte integrins and collagen receptors, respectively, and are being investigated in the new fields of pharmaceutical research. This review summarizes the biological activities of snake venom disintegrins, as well as discusses their potential in the study of the pharmacology of various human diseases.
Export Options
About this article
Cite this article as:
Marcinkiewicz Cezary, Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication, Current Pharmaceutical Design 2005; 11 (7) . https://dx.doi.org/10.2174/1381612053381765
DOI https://dx.doi.org/10.2174/1381612053381765 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Ovary Feels Fine when Paracrine and Autocrine Networks Cooperate with Gonadotropins in the Regulation of Folliculogenesis
Current Pharmaceutical Design Multidisciplinary Treatment of Early Stage Endometrial Cancer
Anti-Cancer Agents in Medicinal Chemistry New Drugs, Old Fashioned Ways: ER Stress Induced Cell Death
Current Pharmaceutical Biotechnology Neutrophil Elastase as a Target in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry miR-21, miR-106b and miR-375 as Novel Potential Biomarkers for Laryngeal Squamous Cell Carcinoma
Current Pharmaceutical Biotechnology Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine New Antiangiogenetic Therapy Beyond Bevacizumab in the Treatment of Advanced Non Small Cell Lung Cancer
Current Pharmaceutical Design Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry Evaluation of Vitamin C as a Personalized Adjuvant Medicine: Pharmacogenomic Studies
Current Pharmacogenomics and Personalized Medicine Privileged Scaffolds Targeting Bromodomain-containing Protein 4
Current Topics in Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment
Mini-Reviews in Medicinal Chemistry Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology Epigallocatechin-3-Gallate Prevents Autoimmune-Associated Down- Regulation of p21 in Salivary Gland Cells Through a p53-Independent Pathway
Inflammation & Allergy - Drug Targets (Discontinued)